Randomized, Multicenter, Double-Blind, Placebo-Controlled Efficacy and Safety Study of 8 mg PEG-Uricase in Two Dose Regimens in Hyperuricemic Subjects With Symptomatic Gout

Trial Profile

Randomized, Multicenter, Double-Blind, Placebo-Controlled Efficacy and Safety Study of 8 mg PEG-Uricase in Two Dose Regimens in Hyperuricemic Subjects With Symptomatic Gout

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2018

At a glance

  • Drugs Pegloticase (Primary)
  • Indications Gout
  • Focus Registrational; Therapeutic Use
  • Acronyms GOUT-2
  • Sponsors Savient Pharmaceuticals
  • Most Recent Events

    • 16 Jun 2018 Results of two randomised trials (GOUT-1 and GOUT-2; n=211) assessing the factors associated with the presence of tophi in patients with chronic refractory gout, presented at the 19th Annual Congress of the European League Against Rheumatism
    • 15 Jun 2018 According to a Horizon Pharma media release, results are being presented at the Annual European Congress of Rheumatology (EULAR 2018), June 13 -16, 2018.
    • 15 Jun 2018 Results presented in a Horizon Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top